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Abstract
Objectives: Workers with common mental disorders (CMDs) frequently experience recurrent sickness absence but
scientifically evaluated interventions to prevent recurrences are lacking. The objectives of this study are to evaluate
the cost-effectiveness and cost-benefit of a problem solving intervention aimed at preventing recurrent sickness
absence in workers with CMDs compared to care as usual.
Methods: An economic evaluation was conducted alongside a cluster-randomised controlled trial with 12 months
follow-up. Treatment providers were randomised to either a 2-day training in the SHARP-at work intervention, i.e. a
problem solving intervention, or care as usual. Effect outcomes were the incidence of recurrent sickness absence
and time to recurrent sickness absence. Self-reported health care utilisation was measured by questionnaires. A
cost-effectiveness analysis (CEA) from the societal perspective and a cost-benefit analysis (CBA) from the
employer’s perspective were conducted.
Results: The CEA showed that the SHARP-at work intervention was more effective but also more expensive than
care as usual. The CBA revealed that employer’s occupational health care costs were significantly higher in the
intervention group compared to care as usual. Overall, the SHARP-at work intervention showed no economic benefit
compared to care as usual.
Conclusions: As implementation of the SHARP-at work intervention might require additional investments, health
care policy makers need to decide if these investments are worthwhile considering the results that can be
accomplished in reducing recurrent sickness absence.
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Introduction
The costs of mental disorders to society are substantial in
terms of medical care consumption, but even more because of
productivity loss due to sickness absence, work disability and
at-the-job productivity loss [1–7]. Common mental disorders
(CMDs, i.e. depressive, anxiety and adjustment disorders), as
opposed to severe mental disorders, account for the majority of
costs related to mental ill-health [7]. However, evidence for
work-related interventions is much more established for severe
mental disorders, such as supported employment programs [8].
In the last decade, several studies have focused on workers
suffering from CMDs and have evaluated interventions to
enhance return to work (RTW) [9–12]. In these studies, RTW
has been defined as endpoint while recent research has shown
that 20% to 30% of the workers who returned to work after
sickness absence due to CMDs experience recurrent sickness
absence [13,14]. Moreover, recurrent sickness absence is
often more serious and long-lasting than the initial sickness
episode due to CMDs [13]. Thus, more attention is needed for
enhancing sustainable RTW of workers with CMDs by
preventing recurrent sickness absence.
The SHARP-at work intervention is developed to prevent
recurrent sickness absence in workers who returned to work
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after sickness absence due to CMDs [15]. The intervention
consists of problem-solving treatment provided by occupational
physicians (OPs). OPs guide workers through a problem-
solving process focused on establishing solutions for problems
and opportunities encountered when back at work.
Furthermore, consultations between the worker and the
supervisor are stimulated by the OP to achieve solutions that
can be readily implemented. The intervention was compared to
care as usual (CAU) in a cluster-randomised controlled trial
(cluster-RCT) and has shown to be effective in reducing
recurrent sickness absence (Arends et al., submitted).
Before implementing the SHARP-at work intervention in the
occupational health care practice, insight is needed in the
relationship between intervention costs and benefits compared
to CAU [16]. Therefore, the objective of this study was to
perform an economic evaluation of the SHARP-at work
intervention compared to CAU. Cost-effectiveness was
evaluated from the societal perspective and cost-benefit from
the societal and employer perspective.
Methods
Study design
An economic evaluation was conducted alongside a cluster-
RCT. OPs, who conducted the intervention, were recruited
through 365/ArboNed, one of the largest Occupational Health
Services in the Netherlands. The Medical Ethical Board of the
University Medical Center Groningen provided approval for the
study design, the research protocol, questionnaires,
information letters and the informed consent. The trial was
registered in the Dutch Trial Register (NTR) with registration
number NTR1963. More detailed information on the study
design and procedure of the cluster-RCT has been presented
elsewhere [15].
Study setting
In the Netherlands, the employer pays sickness absence
benefits to the sick-listed worker for two years. During these
two years, both the employer and sick-listed worker are
responsible for RTW. The employer is obliged to contract an
OP to help guiding the RTW process. If RTW has not been
accomplished after two years, the Social Security Agency
(SSA) evaluates if sufficient RTW efforts have been made by
the employer and worker and decides on the percentage of
work disability for which the worker will be compensated by the
SSA. Costs for treatment and work accommodations are the
responsibility of the employer, but compensation can be
requested from the SSA for work accommodations.
Study population
Participants were recruited by OPs between January 2010
and June 2011. Eligible participants were workers between 18
and 63 years, had to be diagnosed with a CMD by their OP at
the start of sickness absence and had to be ready to (partially
or fully) RTW. A detailed overview of all inclusion and exclusion
criteria has been presented elsewhere [15].
Randomisation and blinding
OPs were randomised to the intervention or control group
based on a computer-generated random allocation sequence
because workers could not be randomly allocated to OPs as
OPs are bound to companies. Since a worker’s allocation was
predefined based on the OP’s allocation, we only provided
information on the treatment the worker would receive and
blinded the worker for study design and comparison group.
OPs were not blinded for study design and allocation.
Interventions
SHARP-at work intervention.  A detailed description of the
intervention has been provided elsewhere (Arends et al.,
submitted for publication). In brief, the SHARP-at work
intervention was developed to prevent recurrent sickness
absence by structured OP guidance after RTW. The
intervention was started by OPs when participants on sickness
absence due to CMDs were ready to RTW. Five steps had to
be followed by the participant when RTW was started. The OP
monitored that all steps were taken and activated the
participant when needed. For each step, facilitating
assignments for the worker were at the OP’s disposal. The five
steps comprised: (1) making an inventory of problems and/or
opportunities encountered at work after RTW, (2) brainstorming
about solutions/realisations, (3) writing down solutions/
realisations and the support needed and assessing the
applicability of these solutions, (4) discussing solutions/
realisations and making an action plan with the supervisor, and
(5) evaluating the action plan/implementation of solutions. Two
to five consultations, of 30 minutes each, were recommended
to OPs. The first of five assignments (i.e. making an inventory
of problems and opportunities and assessing the help needed
to solve them) instigated the problem solving process and was
therefore a key element. OPs received a two-day training in the
SHARP-at work intervention and had three feedback moments
to discuss their experiences with conducting the intervention.
Care as usual.  All participating OPs were already trained in
the evidence-based guideline of the Netherlands Society of
Occupational Medicine “The treatment of workers with mental
health problems by the OP” [17,18]. The guideline is primarily
directed at structuring OP’s treatment to help sick-listed
workers with mental health problems to RTW. Though one
consultation has to take place after RTW to address relapse
prevention, limited attention is given to a structured follow-up of
OP’s treatment after RTW has been accomplished.
Economic evaluation
An economic evaluation was performed from the societal and
employer perspective. The evaluation from the societal
perspective consisted of a cost-effectiveness analysis (CEA)
with the difference in incidence of recurrent sickness absence
and time to recurrent sickness absence between the two study
groups as the outcomes. Costs associated with health care
utilisation (including the costs for the intervention or CAU) were
included in the CEA. From the employer perspective, a cost-
benefit analysis (CBA) was performed comparing the two study
groups regarding costs associated with health care utilisation
SHARP-At Work Intervention; An Economic Evaluation
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(including the costs for the intervention or CAU) and the
monetary value of differences in productivity.
Effects.  The effect measures for the CEA were incidence of
recurrent sickness absence and time to recurrent sickness
absence during 12 months follow-up. Recurrent sickness
absence was defined as ≥ 30% decrease in working days per
week due to sickness absence, regardless of partial or full
RTW. Recurrent sickness absence days were corrected for
partial RTW by dividing the sickness absence days by 1/RTW
percentage.
Health care costs.  Data were collected using the Trimbos/
iMTA questionnaire for Costs associated with Psychiatric
Illness (TiC–P) with a 4-week recall period at baseline and at 3,
6 and 12 months follow-up. The data were linearly interpolated
over 12 months. The unit prices used for valuing resource
utilisation are presented in Table 1. The study’s index year was
2009. The Dutch Manual for Costing was used for calculating
standard prices [19]. Costs for alternative care were based on
real costs reported by the participants. Medication costs were
valued with cost prices of the Royal Dutch Society for
Pharmacy [20]. Two questions on number of consultations with
the OP and company social worker were added to the Tic-P to
collect data on use of occupational health services. For the
calculation of costs from the societal perspective, the OP
consultations were valued using the cost level for general
practitioners, and consultations with the company social worker
were valued using the cost level for social workers. For the
calculation of costs from the employer perspective real
employer prices for OPs and company social workers were
used which were provided by the Occupational Health Service.
Productivity loss.  For the CBA, productivity loss was
operationalized as costs resulting from sickness absence and
at-work productivity loss (i.e. presenteeism). To measure
sickness absence costs, administrative data were collected on
Table 1. Unit prices used and mean (SD) total costs per study group.
 Mean costs (SD)
Type of costs Unit prices SHARP CAU
Health care costs for society    
General practitioner 29a 59 (63) 61 (70)
Regional Institute for Community Mental Health Care 70a 69 (140) 96 (194)
Psychiatrist 107a 22 (74) 67 (212)
Psychologist 83a 212 (228) 209 (205)
Occupational physician 29 81 (48) 60 (46)
Company social worker 68 34 (80) 16 (48)
Medical specialist 75a 103 (239) 91 (208)
Physiotherapist 37a 61 (138) 68 (118)
Social worker 68a 15 (52) 15 (80)
Alternative health care 31-64c 66 (137) 91 (189)
Psychiatric part-time or day program 200a 48 (347) 27 (186)
Hospitalisation 452-597a 164 (1000) 42 (163)
Prescribed medication Variableb 43 (83) 38 (65)
Self-purchased medication Variablec 33 (105) 80 (158)
Out-of-pocket costs Variablec 29 (109) 38 (159)
SHARP-at work intervention 661 661 0
Total health care costs  4167 (9407) 2403 (2360)
Costs of occupational health services for employer
Occupational physician 154 420 (250) 314 (240)
Company social worker 121 248 (239) 178 (125)
SHARP-at work intervention 661 661 0
Total costs of occupational health services  1143 (342) 343 (254)
Costs of productivity loss
Productivity loss net HCA
Only sickness absence  37265 (26227) 32019 (22442)
Combinedd  36072 (20015) 31342 (24039)
Productivity loss net FCA
Only sickness absence  27789 (17185) 24594 (15993)
Combinedd  28194 (14529) 24264 (18069)
All costs are given in euros. SHARP = intervention group; CAU = care as usual; HCA = human capital approach; FCA = friction cost approach.
a. Price according to Dutch guidelines for costing studies.
b. Price according to the Royal Dutch Society for Pharmacy
c. Price according to self-report of participants
d. Productivity loss costs are a combination of sickness absence costs and costs due to lost productivity at work (based on N=35 in SHARP group and N=37 in CAU group).
SHARP-At Work Intervention; An Economic Evaluation
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cumulative number of days of sickness absence over a period
of 12 months. Calendar days of sickness absence were
corrected for part-time sickness absence and converted to
number of working hours based on participants’' work contract.
For the calculation of productivity loss costs, we assumed that
participants were 100% productive during the hours of work
resumption. At-work productivity loss was assessed with one
question of the TiC–P stating: "How many extra hours would
you have to work to catch up on tasks you were unable to
complete in normal working hours due to health problems over
the past two weeks?" Sickness absence costs and costs for at-
work productivity loss were calculated by multiplying the
number of sickness absence hours by the estimated cost of
production loss for a worker per hour of absence, differentiating
between costs for men and women. We used the Human
Capital Approach (HCA) and the Friction Cost Approach (FCA)
to calculate the total costs of production loss. A friction period
of 154 days and an elasticity of 0.8 were applied in the FCA
[19,21].
Data analysis
The economic evaluation was performed according to the
intention-to-treat principle. Discounting of costs was not applied
because the follow-up was limited to one year. Sickness
absence data were collected for 145 (92%) participants and a
complete follow-up on self-reported data was available for 99
(63%) participants.
For the CEA, the incremental cost-effectiveness ratio (ICER)
was calculated by dividing the incremental costs by the
incremental effects. The incremental costs consisted of the
difference in all health care utilisation costs (including the
intervention costs) between the intervention and control group.
Two incremental effect measures were calculated: (1) the
difference in incidence of recurrent sickness absence and (2)
the difference in time (measured in days) to recurrent sickness
absence between the intervention and control group. The ICER
represents the additional investments needed to prevent one
case of recurrent sickness absence or to prevent one day of
recurrent sickness absence. For the CBA from the employer’s
perspective, the net monetary benefit (NMB) was calculated by
subtracting the difference in costs for occupational health
services (including the intervention costs) between the
intervention and control group from the difference in costs of
productivity loss between the two groups. Total costs of
productivity loss was calculated with and without costs due lost
productivity at work, next to costs of sickness absence, as data
on lost productivity at work were only available for 51% of the
study sample. The CBA was performed using both the HCA
and FCA. The mean difference in costs and benefits between
the intervention and control group and the 95% confidence
intervals (CI) were calculated with multilevel regression
analysis to account for the study’s multilevel design (i.e.
adjusting for the influence at the OP-level as participants were
nested in OPs).
The 95% CIs for the incremental costs were estimated using
a bias corrected and accelerated bootstrapping procedure with
5000 replications [22]. Bootstrapped cost-effect pairs were
plotted on a cost-effectiveness plane. Cost-effectiveness
acceptability curves were generated if the ICER was located in
the north-east quadrant [23]. Sensitivity analysis for the CEA
was conducted to assess the effect of one extreme outlier.
Sensitivity analyses for the CEA and CBA were conducted to
assess the effect of reducing the intervention costs to €30 per
participant. This reduction in costs was calculated under the
assumption that, in practice, OPs will treat more workers
according to the intervention than the 80 workers that were
included in the intervention group of the present study. In this
way, the training costs of the intervention could be divided over
more workers causing a reduction in intervention costs per
worker. Based on the OHS’s data, every OP treats 2500 to
3000 workers of which 32 to 39 experience sickness absence
due to CMDs within one year [15]. Taking the conservative
assumption that OPs can treat 24 of the 32 to 39 workers
according to the intervention per year, the intervention training
costs for the 73 OPs that participated in the study can be
divided over 1752 (73 x 24) workers, leading to a total amount
of €30 per worker instead of €661 (see also Table 2). Data
processing was performed in SPSS 20.0. Calculation of CIs
and CEA analyses were conducted in R [24].
Results
Participants
OPs recruited 212 workers of whom 158 agreed to
participate. Eighty participants were treated by OPs in the




Costs for training OPs in the intervention
Trainer costs1 Preparation of training: 2 trainers, 2-10hours, €100 per hour 1200
 Training sessions: 2 trainers, 12-108hours, €100 per hour 12000
 Follow-up meetings: 1 trainer, 6 hours,€100 per hour 600
OP attendance
costs2
Training of OPs: 73 OPs, 12 hours, €40
per hour 35040
 Follow-up meetings: 40 OPs, 1,5 hours,€40 per hour 2400
Additional training
costs
Rent for training location, refreshments
and study materials2 1660
Total training costs Sum of trainer costs, OP attendancecosts and additional training costs 52900
Training costs per
worker





Total training costs divided by 1740
workers 30
OP = occupational physician
1. Based on price requested by trainer.
2. Based on OP’s mean wage paid by the Occupational Health Service that was
responsible for training the OPs.
SHARP-At Work Intervention; An Economic Evaluation
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e71937
intervention group and received the SHARP-at work
intervention, and 78 participants were treated by OPs in the
control group and received CAU. Baseline characteristics of the
study population are presented in Table 3.
Effects on recurrent sickness absence
The incidence of recurrent sickness absence during 12
months follow-up was 39% for the SHARP group and 62% for
the CAU group. Based on the bootstrap procedure, the mean
effect difference between the SHARP and CAU group was 24%
(95% CI 3% to 45%) in favour of the SHARP group (Table 4).
The median number of days to recurrent sickness absence was
Table 3. Baseline characteristics of the study population.
 SHARP (n = 80)  CAU (n = 78)
Characteristics M / n SD / %  M / n SD / %
Socio-demographic characteristics    
Age (years) 41.3 9.4  43.3 9.8
Gender (male) 27 33.8  38 48.7
Marital status (married or living together) 67 83.8  60 76.9
Breadwinner (yes) 40 50.0  49 62.8
Educational level       
 Low 6 7.5  13 16.7
 Intermediate 36 45.0  40 51.3
 High 38 47.5  23 29.5
Clinical characteristics    
ICD diagnosis by OP       
 F32.9 Depressive episode, unspecified 4 5.0  12 15.4
 F41.9 Anxiety disorder, unspecified 0 0.0  2 2.6
 F43.2 Adjustment disorders 58 72.5  39 50.0
 F43.9 Reaction to severe stress, unspecified 1 1.25  0 0.0
 R45 Symptoms and signs involving emotional state 7 8.75  14 17.9
 Z73.0 Burn-out 2 2.5  7 9.0
 Other 8 10.0  4 5.1
Work-related characteristics    
Type of occupation    
 Commercial service providers 23 28.8  11 14.1
 Management 11 13.8  15 19.2
 Administrative staff 19 23.8  12 15.4
 ICT staff 4 5.0  4 5.1
 Sales staff 2 2.5  5 6.4
 Health care providers 12 15.0  12 15.4
 Hotel and catering staff 3 3.8  0 0.0
 Stock and/or transport staff 1 1.3  11 14.1
 Designers/planners 3 3.8  2 2.6
 Mechanics/repairmen 2 2.5  5 6.4
Employment (hours per week) 32.6 7.0  32.9 7.3
Irregular work (e.g. shift work) 6 7.5  10 12.8
Executive/manager responsibilities 23 28.8  21 26.9
Duration of sickness absence 130.9 94.2  99.3 66.1
WRFQ-Total score 66.9 15.5  61.0 20.0
Health-related characteristics    
4DSQ Distress 13.8 7.5  15.5 7.5
 Depression 1.5 2.1  2.0 2.4
 Anxiety 3.1 3.3  3.6 3.5
 Somatization 7.9 5.3  7.9 5.5
HADS Depression 7.0 4.5  7.3 4.4
 Anxiety 7.2 3.9  7.8 3.4
SHARP = intervention group; CAU = care as usual group; OP = occupational physician; WRFQ = Work Role Functioning Questionnaire; 4DSQ = Four-Dimensional
Symptom Questionnaire; HADS = Hospital Anxiety and Depression, Scales; M = mean; SD = standard differentiation
SHARP-At Work Intervention; An Economic Evaluation
PLOS ONE | www.plosone.org 5 August 2013 | Volume 8 | Issue 8 | e71937
365 (inter quartile range (IQR) 174 to 365) in the SHARP group
(i.e. 50% of the participants in the SHARP group did not have a
recurrent sickness absence episode within the 12 months
follow-up) and 253 (IQR 117 to 365) in the CAU group. The
mean effect difference between the SHARP and CAU group
was 55 (95% CI 2.85 to 106.09) days in favour of the SHARP
group, i.e. the SHARP group experienced recurrent sickness
absence 55 days later than the CAU group (Table 4).
Health care and productivity loss costs
The mean costs of health care utilisation are presented in
Table 2. An important cost driver was care by the psychologist.
There were small differences between the SHARP and CAU
group regarding non-occupational health care use. The SHARP
Table 4. Mean cost and effect differences between the
SHARP and CAU group.
Analysisa  ΔC (95% CI)  ΔE (95% CI)   
 euros  
percentage/days/
eurosd ICER NMBe
Total group      
 CEA-incidence ofRSA
1932 (-318 to
5350)  0.24 (0.03 to 0.45) 10605  
 CEA-time to RSA 1358 (-945 to4886)  55 (2.85 to 106.09) 2183  
 CBA HCA onlysickness absence 800 (678 to 922)  
5246 (-2701 to
13192)  6046
 CBA FCA onlysickness absence 800 (678 to 922)  
3195 (-2214 to
8604)  3995
 CBA HCAcombinedb 800 (678 to 922)  
4730 (-5699 to
15158)  5530
 CBA FCAcombinedb 800 (678 to 922)  
3929 (-3764 to
11623)  4729
Excluding outlierc      
 CEA-incidence ofRSA
-133 (-1155 to
914)  0.25 (0.03 to 0.46) -533  
 CEA-time to RSA -129 (-1266 to964)  59 (5.95 to 111.15) -2  
CEA = cost effectiveness analysis; RSA = recurrent sickness absence; CBA = cost
benefit analysis; ΔC = mean cost difference; ΔE = mean effect difference; HCA =
human capital approach; FCA = friction cost approach; ICER = incremental cost
effect ration; NMB = net monetary benefit
a. In the CEA, ΔC is the mean difference in total health care costs and ΔE is the
mean difference in percentage of workers that experienced recurrent sickness
absence; in the CBA, ΔC is the mean difference in total occupational health care
costs, including the intervention, for the employer and ΔE is the mean difference in
sickness absence costs estimated by the HCA or FCA.
b. Productivity loss costs are a combination of sickness absence costs and costs
due to lost productivity at work.
c. Sensitivity analysis excluding one extreme outlier.
d. Differences in CEA effects are presented in (1) percentage of workers that
experienced recurrent sickness absence, (2) number of days to recurrent sickness
absence; differences in CBA effects are presented as costs in euros.
e. Negative values of the NMB imply lower costs for the intervention group
compared to the control group.
group more frequently visited the OP and company social
worker. Following this, total occupational health care costs for
the employer were significantly higher in the SHARP group
(Table 4). The costs of the SHARP-at work intervention were
€661 per worker. We also calculated the intervention costs
based on the assumption that, in practice, every OP could treat
at least 24 workers according to the intervention lowering
intervention costs per worker to €30 (Table 2). The difference
in mean total health care costs between the two study groups
was mainly due to one outlier in the SHARP group whose total
health care costs were more than nine times higher than the
upper limit of the 95% CI of the total health care costs of the
SHARP group. The high costs for this outlier were mainly due
to hospitalisation in a psychiatric ward.
No significant differences were found between the SHARP
and CAU group regarding cost of productivity loss (Table 4).
For both groups, cost of productivity loss represented 87% to
93% of the total costs, depending on how it was measured
(HCA or FCA).
Cost-effectiveness analysis
The CEA with incidence of recurrent sickness absence as
effect measure showed an ICER of €10.605 per percent of
prevented recurrent sickness absence episode, i.e. an
additional €10.605 were needed in the SHARP group to have
1% less recurrent sickness absence compared to the CAU
group (Table 4). The cost-effectiveness plane showed that 92%
of the bootstrap cost-effectiveness pairs were in the north-east
quadrant (Figure 1A). The cost-effectiveness acceptability
curve showed that if one is willing to invest €20.000 for 1% less
recurrent sickness absence, there is a 84% probability that the
intervention is cost-effective compared to CAU (Figure 1A).
The CEA with time to recurrent sickness absence as effect
measure showed an ICER of €2813 per one day of prevented
recurrent sickness absence, meaning that an additional €2813
was needed in the SHARP group to prevent one day of
recurrent sickness absence. The cost-effectiveness plane
showed that 77% of the bootstrap cost-effectiveness pairs were
in the north-east quadrant (Figure 1B). The cost-effectiveness
acceptability curve showed that if one is willing to invest €70 to
prevent one day of recurrent sickness absence, there is a 85%
probability that the intervention is cost-effective compared to
CAU (Figure 1B). Thus, the SHARP-at work intervention was
more effective but also more costly compared to CAU.
The sensitivity analysis excluding the outlier showed an
ICER of €-533 for the incidence of recurrent sickness absence,
indicating that the intervention was cost-effective: 1% less
recurrent sickness absence saved €533. In the cost-
effectiveness plane 60% of the bootstrap cost-effectiveness
pairs were in the south-east quadrant (Figure 2A). The cost-
effectiveness acceptability curve showed a 98% probability that
the intervention is cost-effective compared to CAU if one is
willing to invest €15.000 for 1% less recurrent sickness
absence (Figure 2A). Similarly, the sensitivity analysis
excluding the outlier changed the direction of the primary
results regarding time to recurrent sickness absence. An ICER
of €-2 was found, indicating that the intervention was cost-
effective compared to care as usual: the prevention of one day
SHARP-At Work Intervention; An Economic Evaluation
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of recurrent sickness absence saved €2. The cost-
effectiveness plane showed that 58% of the bootstrap cost-
effectiveness pairs are in the south-east quadrant (Figure 2B).
The cost-effectiveness acceptability curve showed a 98%
probability that the intervention is cost-effective compared to
CAU if one is willing to invest €70 to prevent one day of
recurrent sickness absence (Figure 2B).
Sensitivity analyses with reduced intervention costs did not
change the direction of the primary analyses.
Cost-benefit analysis
The CBA from the employer’s perspective showed that the
mean cost difference for occupational health services was in
favour of the CAU group. The mean costs were €800 (95% CI
678 to 922) higher in the SHARP group compared to the CAU
group. The mean cost difference for productivity loss was also
in favour of the CAU group. According to the HCA, only
including sickness absence costs, the mean costs for
productivity loss were €5246 (95% CI -2701 to 13192) higher in
the SHARP group. Following the FCA, only including sickness
absence costs, the mean costs for productivity loss were €3195
(95% CI -2214 to 8604) higher in the SHARP group. Thus, no
net monetary benefit was achieved with the SHARP-at work
intervention compared to CAU. The sensitivity analyses with
reduced intervention costs did not change these results.
Discussion
The SHARP- at work intervention had a superior effect on
the incidence of and time to recurrent sickness absence but
had no economic benefit compared to care as usual. From a
societal perspective, there were no significant differences in
health care costs between the SHARP group and CAU group.
Employer costs for occupational health care were significantly
higher in the SHARP group compared to CAU. Costs due to
lost productivity did not significantly differ between the two
study groups. Thus, to realise the effect on recurrent sickness
absence, additional monetary investments in the SHARP-at
work intervention were needed. Even though an economic
benefit of the intervention was not found, a societal benefit may
be realised when the reduction in recurrent sickness absence
results in more stable work participation.
Sensitivity analyses for the CEA excluding one major outlier
changed the direction of the primary CEA results. Excluding the
outlier, the SHARP-at work intervention was cost-effective in
preventing the incidence of recurrent sickness absence and
increasing time to recurrent sickness absence.
Although the SHARP-at work intervention was effective in
reducing the incidence of recurrent sickness absence and
increased the time to recurrent sickness absence, the CBA
showed no effect on reduced costs of productivity loss. This
Figure 1.  Cost-effectiveness planes and acceptability curves for (A) the difference in incidence of recurrent sickness
absence and (B) time to recurrent sickness absence.  
doi: 10.1371/journal.pone.0071937.g001
SHARP-At Work Intervention; An Economic Evaluation
PLOS ONE | www.plosone.org 7 August 2013 | Volume 8 | Issue 8 | e71937
result might be counterintuitive as a reduced incidence of
recurrent sickness absence would be expected to result in
reduced sickness absence days and, thus, reduced costs due
to productivity loss. However, costs due to productivity loss
were found to be somewhat higher for the SHARP group,
meaning that the SHARP group had more sickness absence
days. This result may be partly explained by the fact that the
CAU group had a shorter duration of sickness absence and a
higher RTW percentage at baseline, resulting in less sickness
absence days. Possibly, the study’s one-year follow-up
timeframe was too short to pick up long-term effects on
sickness absence.
No previous studies have been published on an economic
evaluation of an intervention to prevent recurrent sickness
absence in workers who returned to work after sickness
absence due to CMDs. Recently, several studies were
published on economic evaluations of RTW interventions for
workers with mental health problems [25–28]. Comparing our
study results with these RTW studies is complicated as the
study populations and the effect measures differ. The
participants in the RTW studies were still off work and the
interventions aimed to facilitate RTW. Effect measures in the
economic evaluations of these RTW studies are focused on
days to first or full RTW. Most of the RTW studies showed no
economic benefit of the RTW intervention under investigation
[25,27,28].
Strengths and limitations
The strengths of this study are the pragmatic design, data
collection on productivity loss and the use of a societal and
employer perspective for the economic evaluation. Firstly, the
pragmatic study design enabled an economic evaluation of the
SHARP-at work intervention in a real life situation and in a
heterogeneous study population. Participants lived in different
parts of the Netherlands, worked for small and large companies
in different branches and occupied various job positions. This
increased the external validity of the study results. Secondly,
data on productivity loss included costs due to self-reported
lost productivity at work, i.e. presenteeism, next to costs due to
sickness absence. Even though information on productivity loss
at work was only collected for 51% of the study sample, the
CBA including this information gives a clear indication of the
underestimation of productivity loss costs when only using
sickness absence data and assuming that participants are
100% productive when at work. As presenteeism seems to be
an important contributor to productivity loss among workers
with mental health problems, this is an important variable to
include in economic evaluations [6,29,30]. However, previous
Figure 2.  Cost-effectiveness planes and acceptability curves excluding one outlier for (A) the difference in incidence of
recurrent sickness absence and (B) time to recurrent sickness absence.  
doi: 10.1371/journal.pone.0071937.g002
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studies on the economic benefit of occupational health care
interventions for workers with mental health problems often
missed information on presenteeism [26–28]. Lastly, the cost-
effectiveness evaluation from the broad societal perspective
increased the generalisability of the results, while the cost-
benefit analysis from the employer perspective provided a
realistic perspective on the distribution of costs and benefits of
the SHARP-at work intervention within the Dutch social security
context.
Some methodological limitations need to be considered.
Data on health care utilisation were collected based on
retrospective, self-reported questionnaires which may have
biased the results. Although participants received diaries to
keep track of health care utilisation to improve the reliability of
the self-reported questionnaires, these diaries were sent for
participants’ own convenience and not recollected. Thus, we
were not able to check whether the diaries were used.
Furthermore, data on health care utilisation during the past
month were only collected at four measurement points and
were linearly interpolated to 12 months, assuming a linear time
trend in health care utilisation. Health care costs may have
been overestimated or underestimated if health care utilisation
between two time measurements was not linear over time.
However, this probably will not have affected the direction of
our results, as the health care costs only presented a small
proportion of the total costs and data were linearly interpolated
for both study groups. Another limitation is the missing data
due to loss to follow-up: 62% of the participants had complete
cost data. By using a bootstrap procedure with 5000
replications for the CEA, the problem of missing data was
partly averted. Furthermore, we chose to conduct complete
case analysis because we assumed that the data was missing
completely at random: no significant differences were found
between participants who were lost to follow-up and those who
completed the study (Arends et al., submitted for publication).
One exception might have been the data collected on
productivity loss at work. Many participants responded to this
question with a question mark, indicating that participants had
trouble understanding this item. Therefore, we decided to also
conduct the CBA excluding the information on lost productivity
at work. As 62% of the data could be used for the CEA and
CBA and no power calculation was conducted for the economic
evaluation, it could be possible that the study was
underpowered. For example, sensitivity analyses excluding one
major outlier in the intervention group showed that the CEA
results were strongly influenced by this outlier as the direction
of the results changed after excluding the outlier. It should also
be acknowledged that using the wage costs of hours off work
and hours not being productive while at work may not be the
best measures for assessing productivity loss. Productivity loss
also depends on the level of teamwork, the time sensitivity of
output and the replaceability of a worker. Finally, no information
was collected on the costs of workplace adaptations that
possibly resulted from the SHARP-at work intervention. This
might have caused an underestimation of the intervention
costs. However, costs due to possible workplace adaptations
would be difficult to measure in a population of workers with
CMDs. These workers do not so much require adaptations in
workplace equipment or design but are more in need of, for
example, frequent/longer breaks, lower work pace or other job
content [31] of which the costs are hard to estimate.
Comparable workplace adaptations could also have been
introduced in the CAU group, as participants in this group also
had consultations with their OPs. Thus, differences in total
health care costs between the two study groups would
probably not drastically increase by including costs related to
workplace adaptations.
Conclusion
The SHARP-at work intervention is effective in reducing
recurrent sickness absence and in increasing time to recurrent
sickness absence but is associated with higher costs compared
to CAU. Bearing in mind the study’s limitations, future research
needs to confirm that the SHARP-at work intervention is not
cost-effective and cost-beneficial. As implementation of the
SHARP-at work intervention might require additional
investments, health care policy makers need to decide if these
investments are worthwhile considering the results that can be
accomplished in reducing recurrent sickness absence.
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